Tags

Type your tag names separated by a space and hit enter

Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes.
Diabetes Obes Metab. 2019 05; 21(5):1158-1167.DO

Abstract

AIM

To evaluate the effects of the prandial glucagon-like peptide-1 receptor agonist lixisenatide on gastric emptying and blood pressure (BP) and superior mesenteric artery (SMA) blood flow, and the glycaemic responses to a 75-g oral glucose load in healthy people and those with type 2 diabetes (T2DM).

MATERIALS AND METHODS

Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days. All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink.

RESULTS

Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM. Plasma glucose (incremental AUC 0-120 minutes) was greater in participants with T2DM (P < 0.005) than in healthy participants, and lower after lixisenatide in both groups (P < 0.001).

CONCLUSIONS

In healthy participants and those with T2DM, the marked slowing of gastric emptying of glucose induced by lixisenatide was associated with attenuation of the increments in glycaemia and SMA flow and decrease in systolic BP. Accordingly, lixisenatide may be useful in the management of postprandial hypotension.

Authors+Show Affiliations

Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia. Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia. Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. National Health and Medical Research Council (NHMRC), Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, South Australia, Australia. Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

30623563

Citation

Jones, Karen L., et al. "Effects of Lixisenatide On Postprandial Blood Pressure, Gastric Emptying and Glycaemia in Healthy People and People With Type 2 Diabetes." Diabetes, Obesity & Metabolism, vol. 21, no. 5, 2019, pp. 1158-1167.
Jones KL, Rigda RS, Buttfield MDM, et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes Obes Metab. 2019;21(5):1158-1167.
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., & Horowitz, M. (2019). Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes, Obesity & Metabolism, 21(5), 1158-1167. https://doi.org/10.1111/dom.13633
Jones KL, et al. Effects of Lixisenatide On Postprandial Blood Pressure, Gastric Emptying and Glycaemia in Healthy People and People With Type 2 Diabetes. Diabetes Obes Metab. 2019;21(5):1158-1167. PubMed PMID: 30623563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. AU - Jones,Karen L, AU - Rigda,Rachael S, AU - Buttfield,Madeline D M, AU - Hatzinikolas,Seva, AU - Pham,Hung T, AU - Marathe,Chinmay S, AU - Wu,Tongzhi, AU - Lange,Kylie, AU - Trahair,Laurence G, AU - Rayner,Christopher K, AU - Horowitz,Michael, Y1 - 2019/02/14/ PY - 2018/10/10/received PY - 2018/12/26/revised PY - 2019/01/04/accepted PY - 2019/1/10/pubmed PY - 2020/3/31/medline PY - 2019/1/10/entrez KW - blood pressure KW - gastric emptying KW - lixisenatide KW - postprandial hypotension KW - type 2 diabetes SP - 1158 EP - 1167 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 21 IS - 5 N2 - AIM: To evaluate the effects of the prandial glucagon-like peptide-1 receptor agonist lixisenatide on gastric emptying and blood pressure (BP) and superior mesenteric artery (SMA) blood flow, and the glycaemic responses to a 75-g oral glucose load in healthy people and those with type 2 diabetes (T2DM). MATERIALS AND METHODS: Fifteen healthy participants (nine men, six women; mean ± SEM age 67.2 ± 2.3 years) and 15 participants with T2DM (nine men, six women; mean ± SEM age 61.9 ± 2.3 years) underwent measurement of gastric emptying, BP, SMA flow and plasma glucose 180 minutes after a radiolabelled 75-g glucose drink on two separate days. All participants received lixisenatide (10 μg subcutaneously) or placebo in a randomized, double-blind, crossover fashion 30 minutes before the glucose drink. RESULTS: Lixisenatide slowed gastric emptying (retention at 120 minutes, P < 0.01), attenuated the rise in SMA flow (P < 0.01) and markedly attenuated the decrease in systolic BP (area under the curve [AUC] 0-120 minutes, P < 0.001) compared to placebo in healthy participants and those with T2DM. Plasma glucose (incremental AUC 0-120 minutes) was greater in participants with T2DM (P < 0.005) than in healthy participants, and lower after lixisenatide in both groups (P < 0.001). CONCLUSIONS: In healthy participants and those with T2DM, the marked slowing of gastric emptying of glucose induced by lixisenatide was associated with attenuation of the increments in glycaemia and SMA flow and decrease in systolic BP. Accordingly, lixisenatide may be useful in the management of postprandial hypotension. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/30623563/Effects_of_lixisenatide_on_postprandial_blood_pressure_gastric_emptying_and_glycaemia_in_healthy_people_and_people_with_type_2_diabetes_ L2 - https://doi.org/10.1111/dom.13633 DB - PRIME DP - Unbound Medicine ER -